Successful response to docetaxel treatment in recurrent ovarian granulosa cell tumor: a case report

Background: Ovarian granulosa cell tumor (GCT) is primarily treated surgically. Treatment for advanced or recurrent disease includes primary or adjuvant chemotherapy. Data about the efficacy of treatment with paclitaxel are limited, without data about the role of docetaxel in treating recurrent GCT. Case: A 68-year-old patient with Stage IA ovarian GCT diagnosed ten years earlier, presented with a third episode of recurrent disease. Following the first event of recurrent disease, she underwent a second laparotomy followed by BEP chemotherapy. Because of new liver masses, she was treated with paclitaxel, with complete response. Following diagnosis of new liver lesions, third-line chemotherapy with docetaxel was initiated, resulting in stable disease and a PFI of 24 months. Conclusion: Docetaxel might be a good alternative for treating recurrent GCT.

Granulosa cell tumor; Docetaxel

[1] Colombo N., Parma G., Zanagnolo V., Insinga A.: “Management of ovarian stromal tumors”. J. Clin. Oncol., 2007, 25, 2944.

[2] Gershenson D.M., Copeland L.J., Kavanagh J.J., Stringer C.A., Saul P.B., Wharton J.T.: “Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide”. Obstet. Gynecol., 1987, 70, 765.

[3] Gershenson DM, Morris M, Burke TW., Levenback C., Matthews C.M., Wharton J.T.: “Treatment of poor-prognosis sex cordstromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin”. Obstet. Gynecol., 1996, 87, 527.

[4] Brown J., Shavartsman H.S., Deavers M.T., Burke T.W., Munsell M.F., Gershenson D.M.: “The activity of taxanes in the treatment of sex cord-stromal ovarian tumors”. J. Clin. Oncol., 2004, 22, 3517.

[5] Tresukosol D., Kudelka A.P., Edwards C.L., Charnsangavej C., Narboni N., Kavanagh J.J.: “Recurrent ovarian granulose cell tumor: a case report of a dramatic response to Taxol”. J. Gynecol. Cancer, 1995, 5, 156.

[6] Powell J.L., Connor G.P., Henderson G.S.: “Management of recurrent juvenile granulosa cell tumor of the ovary”. Gynecol. Oncol., 2001, 81, 113.

[7] Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M. et al.: “Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer”. J. Clin. Oncol., 1994, 12, 2301.

[8] Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R. et al.: “Phase III randomized trial of docetaxel-carboplatin versus paclitacel-carboplatin as first-line chemotherapy for ovarian carcinoma”. J. Nation Cancer Instit., 2004, 96, 1682.

[9] Homesley H.D., Bundy B.N., Hurteau J.A., Roth L.M.: “Bleomycin, etoposide, and cisplatin combination chemotherapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1999, 72, 131.

[10] Brown J., Shvartsman H.S., Deavers M., Ramondetta L.M., Burke T.W., Munsell M.F., Gershenson D.M.: “The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors”. Gynecol. Oncol., 2005, 97, 489.